FGF2, but not FGF1, was shown to enhance cisplatin toxicity in MCF-7 breast cancer cells and A2780 ovarian cancer cells, but not in SKOV3 ovarian cancer cells or a panel of pancreatic cancer cell lines. Here, FGF2 is linked to breast cancer.